Evidence map›Paper›PMID 41341045›Full record

ArticleACS central science2025

Targeted NAT10 Degradation by PROTAC NP1192 Suppresses Hypoxia-Adaptive Glycolysis and Reinvigorates CD8

Keyi Ao, Zhiqiang Sun, Yi Hao, Jiaqi Qin, Chenglong Xu, Xiuli Wen, Zichao Yang, Li Li, Shaoyan Gan, Xiaona Chen and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS central science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Keyi AoShenzhen Key Laboratory of Viral Oncology, Department of Science and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong 518100, P. R. China.
Zhiqiang SunGuangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong 510515, P. R. China.
Yi HaoDepartment of Ultrasound, South China Hospital, Medical School, Shenzhen University, Shenzhen, Guangdong 518116, P. R. China.
Jiaqi QinShenzhen Key Laboratory of Viral Oncology, Department of Science and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong 518100, P. R. China.
Chenglong XuGuangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong 510515, P. R. China.
Xiuli WenDepartment of Ultrasound, South China Hospital, Medical School, Shenzhen University, Shenzhen, Guangdong 518116, P. R. China.
Zichao YangGuangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong 510515, P. R. China.
Li LiShenzhen Key Laboratory of Viral Oncology, Department of Science and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong 518100, P. R. China.
Shaoyan GanShenzhen Key Laboratory of Viral Oncology, Department of Science and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong 518100, P. R. China.
Xiaona ChenShenzhen Key Laboratory of Viral Oncology, Department of Science and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong 518100, P. R. China.
Xin LiShenzhen Key Laboratory of Viral Oncology, Department of Science and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong 518100, P. R. China.
Jian ZhangDepartment of Human Cell Biology and Genetics, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong 518055, P. R. China.
Jianjun ChenGuangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong 510515, P. R. China.ORCID https://orcid.org/0000-0001-5668-6572
Xia GuoShenzhen Key Laboratory of Viral Oncology, Department of Science and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong 518100, P. R. China.ORCID https://orcid.org/0000-0002-6022-9128

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor resistance to immune checkpoint blockade (ICB) therapy is frequently driven by adaptive metabolic reprogramming in the hypoxic tumor microenvironment (TME). The key N4-acetylcytidine (ac4C) RNA modification mediator N-acetyltransferase 10 (NAT10) emerges as a promising therapeutic target, despite the lack of potent targeting agents. Here, we engineered NP1192, a PROTAC degrader targeting NAT10. NP1192 achieved nearly 70% NAT10 degradation and a 26.8% lower IC

Identifiers

PMID41341045
PMCPMC12670317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.